ZYME Zymeworks Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZYME

Price (delayed)

$27.5

Market cap

$1.95B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$2.04B

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 25

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

Highlights
ZYME's EPS has dropped by 106% year-on-year and by 47% since the previous quarter
Zymeworks's net income has shrunk by 104% YoY and by 46% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.zymeworks.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ZYME

ZYME stock price

How has the Zymeworks stock price performed over time
Intraday
-0.24%
1 week
4.8%
1 month
-4.08%
1 year
68.09%
YTD
4.44%
QTD
5.2%

Financial performance

How have Zymeworks's revenue and profit performed over time
Revenue
$37.13M
Gross profit
$37.13M
Operating income
-$155.56M
Net income
-$149.99M
Gross margin
100%
Net margin
-404%
The operating margin has plunged by 198% from the previous quarter
Zymeworks's net income has shrunk by 104% YoY and by 46% QoQ
ZYME's operating income has dropped by 88% year-on-year and by 36% since the previous quarter
Zymeworks's gross profit has shrunk by 70% YoY and by 54% QoQ

Price vs fundamentals

How does ZYME's price correlate with its fundamentals

Growth

What is Zymeworks's growth rate over time

Valuation

What is Zymeworks stock price valuation
ZYME P/E details
P/E
N/A
P/B
24.99
P/S
54.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
54.96
ZYME's EPS has dropped by 106% year-on-year and by 47% since the previous quarter
ZYME's P/B is 116% above its last 4 quarters average of 11.6
The company's equity has shrunk by 76% YoY and by 51% QoQ
The stock's price to sales (P/S) is 111% more than its last 4 quarters average of 25.7
Zymeworks's revenue has plunged by 70% YoY and by 54% from the previous quarter

Efficiency

How efficient is Zymeworks business performance
Zymeworks's ROA has plunged by 125% YoY and by 47% from the previous quarter
Zymeworks's return on equity has shrunk by 91% QoQ
ZYME's ROIC has dropped by 70% year-on-year and by 26% since the previous quarter

Dividends

What is ZYME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZYME.

Financial health

How did Zymeworks financials performed over time
Zymeworks's total assets is 25% higher than its total liabilities
The quick ratio has declined by 43% since the previous quarter and by 21% year-on-year
The company's current ratio fell by 42% QoQ and by 18% YoY
The debt to equity has soared by 107% since the previous quarter
The company's equity has shrunk by 76% YoY and by 51% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.